Skip to main content
Top
Published in: Clinical Rheumatology 5/2013

01-05-2013 | Case Based Review

Antisynthetase antibody syndrome: case report and review of the literature

Authors: Laura Uribe, Diana Maria Ronderos, Maria Claudia Díaz, Juan Martín Gutierrez, Christina Mallarino, Daniel Gerardo Fernandez-Avila

Published in: Clinical Rheumatology | Issue 5/2013

Login to get access

Abstract

Antisynthetase antibody syndrome is a rare autoimmune disease that may present with variable systemic manifestations, mainly polymyositis, interstitial lung disease, skin lesions, and Raynaud’s phenomenon. This diagnosis should always come to mind in patients that present with signs of myositis, dermatomyositis, or polymyositis associated with interstitial lung disease. On the following paper, we report the case of a 52-year-old man who presented with a 2-month history of asymmetric polyarthralgia, myalgia, weight loss of 8 kg, and progressive muscle weakness associated with dyspnea, orthopnea, and dysphonia. Further tests revealed myositis, interstitial pneumonia, and elevation of anti-Jo-1 antibodies. A diagnosis of antisynthetase antibody syndrome was made and the patient showed good response to treatment with corticoids and methotrexate. Finally, we present a short review of the literature.
Literature
1.
go back to reference Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M (1984) Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol 11:663–665PubMed Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M (1984) Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol 11:663–665PubMed
2.
go back to reference Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Med (Baltimore) 70:360–374CrossRef Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Med (Baltimore) 70:360–374CrossRef
4.
go back to reference Labirua-Iturburu A, Trallero Araguás E, Selva O’Callaghan A (2010) Síndrome por anticuerpos antisintetasa. Med Clin (Barc) 137(2):77–83CrossRef Labirua-Iturburu A, Trallero Araguás E, Selva O’Callaghan A (2010) Síndrome por anticuerpos antisintetasa. Med Clin (Barc) 137(2):77–83CrossRef
5.
go back to reference Katzap E, Barilla-La Barca ML, Marder G (2011) Antisynthetase syndrome. Curr Rheumatol Rep 13:175–181PubMedCrossRef Katzap E, Barilla-La Barca ML, Marder G (2011) Antisynthetase syndrome. Curr Rheumatol Rep 13:175–181PubMedCrossRef
6.
go back to reference Targoff IN, Arnett FC (1990) Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 88:241–251PubMedCrossRef Targoff IN, Arnett FC (1990) Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 88:241–251PubMedCrossRef
7.
go back to reference Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, Fertig N, Oddis CV, Kaminski N, Rosas IO, Ascherman DP (2009) Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody positive interstitial lung disease. Arthritis Rheum 60(7):2183–2192PubMedCrossRef Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, Fertig N, Oddis CV, Kaminski N, Rosas IO, Ascherman DP (2009) Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody positive interstitial lung disease. Arthritis Rheum 60(7):2183–2192PubMedCrossRef
8.
go back to reference Takada K, Nagasaka K, Miyasaka N (2005) Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoinmunity 38(5):383–392CrossRef Takada K, Nagasaka K, Miyasaka N (2005) Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoinmunity 38(5):383–392CrossRef
9.
go back to reference Váncsa A, Csípo I, Németh J, Dévényi K, Gergely L, Dankó K (2009) Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 29(9):989–994PubMedCrossRef Váncsa A, Csípo I, Németh J, Dévényi K, Gergely L, Dankó K (2009) Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 29(9):989–994PubMedCrossRef
10.
go back to reference Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, Casciola-Rosen L, Hong G, Dellaripa PF, Highland KB (2009) Clinical profile of anti-PL-12 autoantibody cohort study and review of the literature. Chest 135:1550–1556PubMedCrossRef Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, Casciola-Rosen L, Hong G, Dellaripa PF, Highland KB (2009) Clinical profile of anti-PL-12 autoantibody cohort study and review of the literature. Chest 135:1550–1556PubMedCrossRef
11.
go back to reference Schnabel A, Reuter M, Biederer J, Richter C, Gross WL (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 32(5):273–284PubMedCrossRef Schnabel A, Reuter M, Biederer J, Richter C, Gross WL (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 32(5):273–284PubMedCrossRef
12.
go back to reference Friedman AW, Targoff IN, Arnett FC (1996) Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Reum 26:459–467CrossRef Friedman AW, Targoff IN, Arnett FC (1996) Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Reum 26:459–467CrossRef
13.
go back to reference Hervier B, Wallaert B, Hachulla E, Adoue D, Lauque D, Audrain M, Camara B, Fournie B, Couret B, Hatron PY, Dubucquoi S, Hamidou M (2010) Clinical manifestations of antisynthetase syndrome positive for antialanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology 49:972–976PubMedCrossRef Hervier B, Wallaert B, Hachulla E, Adoue D, Lauque D, Audrain M, Camara B, Fournie B, Couret B, Hatron PY, Dubucquoi S, Hamidou M (2010) Clinical manifestations of antisynthetase syndrome positive for antialanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology 49:972–976PubMedCrossRef
14.
go back to reference Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, Ascherman DP (2007) Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory. Arthritis Rheum 56(9):3125–3131PubMedCrossRef Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, Ascherman DP (2007) Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory. Arthritis Rheum 56(9):3125–3131PubMedCrossRef
15.
go back to reference Sato S, Hirakata M, Kuwana M, Nakamura K, Suwa A, Inada S, Mimori T, Ikeda Y (2005) Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin Exp Rheumatol 23:609–615PubMed Sato S, Hirakata M, Kuwana M, Nakamura K, Suwa A, Inada S, Mimori T, Ikeda Y (2005) Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin Exp Rheumatol 23:609–615PubMed
16.
go back to reference Targoff IN (2008) Antisynthetase syndrome. In: Schoenfeld Y, Cervera R, Gershwin ME (eds) Diagnostic criteria in autoimmune diseases. Humana, Totowa, pp 169–174CrossRef Targoff IN (2008) Antisynthetase syndrome. In: Schoenfeld Y, Cervera R, Gershwin ME (eds) Diagnostic criteria in autoimmune diseases. Humana, Totowa, pp 169–174CrossRef
17.
go back to reference Morgenthau AS, Padilla ML (2009) Spectrum of fibrosing diffuse parenchymal lung disease. Mt Sinai J Med 76(1):2–23PubMedCrossRef Morgenthau AS, Padilla ML (2009) Spectrum of fibrosing diffuse parenchymal lung disease. Mt Sinai J Med 76(1):2–23PubMedCrossRef
18.
go back to reference Schnabel A, Reuter M, Biederer J (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 32(5):273–284PubMedCrossRef Schnabel A, Reuter M, Biederer J (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 32(5):273–284PubMedCrossRef
19.
go back to reference Targoff IN (2000) Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 12(6):475–481PubMedCrossRef Targoff IN (2000) Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 12(6):475–481PubMedCrossRef
20.
go back to reference Jankowska M, Butto B, Debska-Slizień A, Rutkowski B (2007) Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome. Rheumatol Int 27(8):775–780PubMedCrossRef Jankowska M, Butto B, Debska-Slizień A, Rutkowski B (2007) Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome. Rheumatol Int 27(8):775–780PubMedCrossRef
21.
go back to reference Guglielmi S, Merz TM, Gugger M, Suter C, Nicod LP (2008) Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J 31(1):213–217PubMedCrossRef Guglielmi S, Merz TM, Gugger M, Suter C, Nicod LP (2008) Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J 31(1):213–217PubMedCrossRef
22.
go back to reference Knoell KA, Hook M, Grice DP, Hendrix JD Jr (1999) Dermatomyositis associated with bronchiolitis obliterans organizing pneumonia (BOOP). JAm Acad Dermatol 40(2 Pt 2):328–30CrossRef Knoell KA, Hook M, Grice DP, Hendrix JD Jr (1999) Dermatomyositis associated with bronchiolitis obliterans organizing pneumonia (BOOP). JAm Acad Dermatol 40(2 Pt 2):328–30CrossRef
23.
go back to reference Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, Ryu JH (2001) Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164(7):1182–1185PubMedCrossRef Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, Ryu JH (2001) Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164(7):1182–1185PubMedCrossRef
24.
go back to reference Hervier B, Masseau A, Mussini JM, Audrain M, Hamidou MA (2009) Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome. Joint Bone Spine 76(5):575–576PubMedCrossRef Hervier B, Masseau A, Mussini JM, Audrain M, Hamidou MA (2009) Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome. Joint Bone Spine 76(5):575–576PubMedCrossRef
25.
go back to reference Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M, IFIGENIA Study Group (2005) High dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353:2229–2242PubMedCrossRef Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M, IFIGENIA Study Group (2005) High dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353:2229–2242PubMedCrossRef
Metadata
Title
Antisynthetase antibody syndrome: case report and review of the literature
Authors
Laura Uribe
Diana Maria Ronderos
Maria Claudia Díaz
Juan Martín Gutierrez
Christina Mallarino
Daniel Gerardo Fernandez-Avila
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2013
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-013-2207-5

Other articles of this Issue 5/2013

Clinical Rheumatology 5/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.